

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7344271

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JUNCAI BAI	05/14/2018
RUOPING ZHANG	05/14/2018
JUN JIA	04/27/2018
JUNFENG ZHOU	04/27/2018
QIAO ZHAO	04/27/2018
GUOQING ZHANG	04/27/2018
RECEIVING PARTY DATA	
Name:	AMBIOPHARM, INC.
Street Address:	1024 DITTMAN CT
City:	BEECH ISLAND
State/Country:	SOUTH CAROLINA
Postal Code:	29842
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	10745441
Patent Number:	11142549
Application Number:	17207215
Application Number:	17397796
Patent Number:	11319346
CORRESPONDENCE DATA	
Fax Number:	(215)972-7725
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	215-972-1089
Email:	patents@saul.com
Correspondent Name:	DOMINGOS J. SILVA
Address Line 1:	SAUL EWING ARNSTEIN & LEHR LLP
Address Line 2:	1500 MARKET STREET, 38TH FLOOR
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19102
ATTORNEY DOCKET NUMBER:	376464-2011US2-US6

PATENT

NAME OF SUBMITTER:	DOMINGOS J. SILVA
SIGNATURE:	/Domingos J. Silva/
DATE SIGNED:	05/23/2022
Total Attachments: 10 source=inventors-ambiopharm-SYN-CTRL00025316#page1.tif source=inventors-ambiopharm-SYN-CTRL00025316#page2.tif source=inventors-ambiopharm-SYN-CTRL00025316#page3.tif source=inventors-ambiopharm-SYN-CTRL00025316#page4.tif source=inventors-ambiopharm-SYN-CTRL00025316#page5.tif source=inventors-ambiopharm-SYN-CTRL00025316#page6.tif source=inventors-ambiopharm-SYN-CTRL00025316#page7.tif source=inventors-ambiopharm-SYN-CTRL00025316#page8.tif source=inventors-ambiopharm-SYN-CTRL00025316#page9.tif source=inventors-ambiopharm-SYN-CTRL00025316#page10.tif	

ASSIGNMENT

Juncai BAI, c/o AMBIOPHARM, INC., 1024 Dittman Court, Beech Island, SC 29842; **Ruoping ZHANG**, c/o AMBIOPHARM, INC., 1024 Dittman Court, Beech Island, SC 29842; **Jun JIA**, residing at 388 Chugong Road Fengxian Sub-Zone, Industrial Park Suite 100, Shanghai 201400 China; **Junfeng ZHOU**, residing at 388 Chugong Road Fengxian Sub-Zone, Industrial Park Suite 100, Shanghai 201400 China; **Qiao ZHAO**, residing at 388 Chugong Road Fengxian Sub-Zone, Industrial Park Suite 100, Shanghai 201400 China; and **Guoqing ZHANG**, residing at 388 Chugong Road Fengxian Sub-Zone, Industrial Park Suite 100, Shanghai 201400 China (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled **ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME**, and which is a:

- (1) ☐ provisional application
(a) ☐ to be filed herewith; or
(b) ☐ bearing Application No. , and filed on ;
- (2) ☒ non-provisional application
(a) ☐ to be filed herewith; or
(b) ☒ bearing Application No. **14/896,019**, and filed on **December 4, 2015**; and/or
- (3) ☐ PCT application
(a) ☐ bearing Application No. , and filed on .
- (4) ☐ a patent application bearing Serial No. , and filed on ;

WHEREAS, AMBIOPHARM, INC., a corporation having its principal place of business at 1024 Dittman Ct, Beech Island, SC 29842 its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by

these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

(a) the Invention(s);

(b) the application(s) for patent identified above;

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and

that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.


The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 14 May 2018

By: 
Juncai BAI

WITNESS: 

Date: 14 May 18

Name: Ruoping Zhang

Date: 14 May 18 By: Ruoping Zhang
Ruoping ZHANG

WITNESS:  Date: 14 May 2018

Name: Chris Bai

Date: 27 APR 18

By: Jun Jia
Jun JIA

WITNESS: Tingting LIU

Date: 27 Apr 18

Name: Tingting LIU

Ruoping Zhang
Ruoping Zhang

27 Apr 18

Date: 27 Apr 18 By: Junfeng Zhou
Junfeng ZHOU

WITNESS: Tingting LIU Date: 27 Apr 18

Name: Tingting LIU

Ruoping Zhang
Ruoping Zhang

27 Apr 18

Date: 27 Apr 18

By: _____

Qiao Zhao
Qiao ZHAO

WITNESS: Ting ting LIU

Date: 27 Apr 18

Name: Ting ting LIU

Ruo Ping Zhang
Ruo ping Zhang

27 Apr 18

Date: 27 APR 18

By: Guoqing Zhang
Guoqing ZHANG

WITNESS: Tingting LIU

Date: 27 APR 18

Name: Tingting LIU

Guoqing Zhang
Guoqing Zhang

27 APR 18

For and on behalf of ASSIGNEE:

Date: 14 May 2018

Signature: 

Name: Chris Bai

Title: CEO

Company: AMBIOPHARM, INC.

WITNESS: Ruoping Zhang

Date: 14 May 2018

Name: Ruoping Zhang